Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
DBCG Skagen 1: 40Gy/15fx noninferior to 50Gy/25fx for 3y arm lymphedema (8.0% vs 9.4%, OR 0.84) with regional nodal RT; LRR, distant recurrence, mortality equivalent.
Breast carried the day. DBCG Skagen 1 extends moderate hypofractionation to regional nodal irradiation, the last holdout where late-morbidity fear kept 50Gy/25fx alive: 15-fraction RNI held noninferior arm lymphedema (OR 0.84) with equivalent LRR, distant recurrence, and mortality. Watch BC mortality numerically favoring 50Gy (HR 1.25) on still-short 5.25y cancer f/u.
read the full digest →Studies · 111
- DBCG Skagen Trial 13y arm lymphedema 8.0% (40Gy/15fx) vs 9.4% (50Gy/25fx), OR 0.84, noninferior; LRR, distant recurrence, and mortality all equivalent.
- PACE-B5yr PROMs comparable for SBRT vs conventional RT: pad-free 91% vs 90%, mod/big urinary leak 6% vs 4%, bowel bother 5% both arms.
- ESTRO Prostate SBRT Consensus Recommendations15-expert ESTRO Delphi consensus on optimising primary prostate SBRT: patient selection, contouring, dose/fractionation, follow-up, and delivery technique.
- ProtecT (secondary analysis: cribriform morphology)Cribriform-negative pts (87%): radical Rx gave no significant 15yr metastasis reduction vs active monitoring; cribriform-negative GG2 matched GG1 risk.
- NRG Oncology/RTOG 0848OS primary EP not met (HR 0.96, 90% CI 0.79-1.18) adding adjuvant CXRT to gemcitabine; node-negative subgroup OS benefit on interaction (P=.0063).
- TROG 08.03 RAVES QOL SubstudyAt 5yr, 16% vs 2% severe urinary leakage aRT vs no RT (p=0.01); sRT timing had no QOL effect.
- STAMPEDE (abiraterone ± enzalutamide, high-risk non-metastatic)MFS HR 0.53 (6yr 82% vs 69%) and OS HR 0.60 adding 2yr abiraterone to ADT in high-risk M0 prostate (85% also had RT).
- TREASUREmOS 6.7 vs 13.4mo (HR 1.55, ns) adding consolidative TRT to atezo maintenance; halted early for SAEs 61% vs 18%.
- EANO Consensus Statement on Radiation NecrosisDelphi consensus (20 experts): 53/57 statements reached ≥80% agreement; perfusion MRI + amino-acid PET to distinguish RN from recurrence, bevacizumab for steroid-refractory RN.
- HYDRANo PFS difference vs conventional RT for either MHFRT type, but dose-escalated MHFRT alone raised late G2+ GI + bowel-QoL decrement; isodose 60/20 clean.
- ASTRO 2024: SBRT for Unfavorable Intermediate-Risk Prostate CancerModern 5-fraction SBRT (1-2% bothersome toxicity vs 10-30% for 2D-era 45fx) is now NCCN-endorsed for UIR prostate; focal-boost de-escalation is next.
- SUPREMO10yr chest-wall recurrence 1.1% vs 2.5% (HR 0.45), no DFS/OS gain, but trial prohibited RNI so tests incomplete PMRT.